IPCA Labs
Download as PPTX, PDF6 likes5,974 views
Ipca Laboratories Ltd. is an Indian pharmaceutical company founded in 1949 that manufactures pharmaceuticals and drugs. It has manufacturing facilities across India and international presences in the US, UK, and other countries. Ipca is the largest manufacturer of anti-malarial drugs in India, with its top formulation brands including Zerodol, Lariago, and Lumerax. The company employs a therapy-focused marketing strategy and maintains divisions for areas like cardiology and neuropsychiatry. Ipca focuses on high value products, entry into the US market through partnerships, ANDA filings, and expanding its product range in therapeutic areas like nephrology.
IPCA Labs
- 1. A Dose of Life
- 2. A Profile On Ipca Laboratories Ltd. Based on Marketing Perspective
- 3. THE BRAND LOGO (It’s Transformation through the time) •Butterfly represents “LIFE at its energetic best” •Molecule in between represents “ Pharmaceutical bent of the Company” •Flight of the butterfly represents “soaring aspirations of the company” and • BLUE color represents “ Health, Healing, Wisdom and Confidence.
- 4. ABOUT THE COMPANY •A Public Ltd. Company •Founded in 1949 by K.B. Mehta and N.S. Tibrawala in Mumbai (INDIA) •Headquarters situated at Mumbai •Current Management Team: Mr. Prem Chandra Godha (Managing Director) Mr. A.K.Jain (Joint Managing Director) •Areas served is worldwide •Products Manufactured: Pharmaceuticals and Drugs •Business Model: Fully integrated Pharmaceutical company mfg. branded and generic formulations, active pharmaceutical ingredients and intermediates
- 5. •Total income in the F.Y. 2012-13: Rs. 2797.08 Crores •Total exports in F.Y. 2012-13: Rs.1716.08 Crores •Manufacturing Facilities: Pithampur (Madhya Pradesh) Athal (Gujrat) Dehradun (Uttarakhand) Kandla (Gujrat) Ratlam (Madhya Pradesh) Indore (Madhya Pradesh) Ankaleshwar (Gujrat) Mahad (Maharashtra) •International Presence: U.S.A., U.K., Australia, New Zealand, Nigeria and China •Marketing Offices (Abroad): Kenya, Philippines, Vietnam, Columbia, Peru, Malaysia, Sri Lanka •Major Subsidiaries: CCPL Soft wares(For Patient Counseling) PADAAV (IPCA Traditional Remedy Center for Ayurvedic Treatment) •At one time the control of the company was held by THE BACHCHANS in 1975
- 6. PRODUCTS MANUFACTURED BY THE COMPANY Ipca is the largest mfr. of anti malarial drugs in INDIA
- 7. TOP FORMULATION BRANDS OF IPCA LABS 1. 2. 3. 4. 5. ZERODOL(Analgesics) LARIAGO(Anti-malarial) HYDROXYCHLOROQUINE PERINORM(anti-emetic) RAPITHER (Anti-malarial) 6. TENORIC (Beta Blockers) 7. LUMERAX (Anti-malarials) 8. ETOVA (Antiinflammatory) 9. FOLITRAX (Anti-cancer)
- 8. MARKETTING DIVISIONS OF THE COMPANY Deals with Cardio-diabetic disorders Deals with cardio diabetic disorders and lipid management Deals with rheumatologic and orthopedic disorders Deals with surgical and non surgical equipments Deals with dermatological disorders Deals with first line treatment of patients
- 10. MAJOR COMPETITORS IN THE MARKET MERCK INDUSTRIES LTD. NATCO PHARMACEUTICALS LTD. UNICHEM LABORATORIES LTD. PLETHICO PHARMACEUTICALS LTD.
- 11. MARKET STRATEGY OF THE COMPANY •Major focus on high value products and reduction in dependence on low value generic products. •Entry of the company in the U.S. markets through tie ups with RANBAXY and HARIATGE Pharma •Aggressive ANDA (Abbreviated New Drug Application) in the U.S. Markets. •Maintaining Therapy focused marketing divisions. •In house clinical research facilities and focusing on the safety and well being of the of the patient. •Exports in over 120 countries across the globe and marketing offices in every major continent. •Continuous introduction of new products in domestic and international markets.
- 12. SWOT ANALYSIS
- 13. STRENGTHS WEAKNESS •Worldwide presence in anti malarial market capturing almost 1/3rd of the market. •Focus on brand building and promotional activities is less. •Large network of wholesalers and sales and marketing executives. •Strong and stable financial position of the company. •Dosage forms against all malarial disorders. •Major attention on formulation segment. •Presence in international market. •Limited and slow market share growth.
- 14. OPPORTUNITIES THREATS •Increasing demand for therapeutic drugs in the Indian and Chinese market. •Reduced funds and infrastructure facilities for public healthcare •Acquisition of more and more research based firms will help increase the therapeutic product range to a great extent. •Expansion in the therapeutic segment in Nutraceutical, nephrology and urology will improve profits. •Depreciating value of currency poses a threat to the research driven activities •Global economic slowdown
- 15. CHANNEL OF DISTRIBUTION OF THE PRODUCTS MODEL “A” MODEL “B”
- 16. CORPORATE SOCIAL RESPONSIBILITIES OF THE COMPANY Health Education and Awareness Employees and Society Development CSR ACTIVITIESAREAS OF OPERATION Health and Safety Environment Management Systems
- 17. PRODUCT LINE, LENGTH AND MIX
- 18. PROMOTIONAL ADVERTISEMENT (Based on U.S.P.)